Skip to content

The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis

The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02050646
Enrollment
16
Registered
2014-01-31
Start date
2013-08-27
Completion date
2021-06-30
Last updated
2021-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Hepatitis

Keywords

Autoimmune hepatitis, Liver dysfunction, Elevated serum auto antibodies

Brief summary

The purpose of this study is to determine whether a salt restriction diet improves immune parameters in patients with autoimmune hepatitis.

Detailed description

The etiology of autoimmune hepatitis (AIH) is unknown although both genetic and environmental factors are thought to be involved. A defect in immune regulation affecting regulatory T cells (Tregs) has been demonstrated in AIH. Tregs function in the maintenance of immune homeostasis by controlling autoreactive immune responses to self-antigens. Rationale: the western diet has been postulated as a potential environmental risk factor for the increasing incidence of autoimmune diseases in developed countries. Data from the investigators' laboratory also suggests that increased dietary salt intake might represent an environmental risk factor for the development of autoimmune diseases through the induction of pathogenic Th17 cells. The dramatic in vitro effects of high salt on the induction of pathogenic Th17 cells from naïve human CD4 cells {Kleinewietfeld, Hafler. Nature. 2013 Apr 25;496(7446):518-22. doi: 10.1038/nature11868.}, and block of in vitro Treg suppression, in line with in vivo effects on worsening murine experimental autoimmune encephalomyelitis (EAE), have prompted the investigators to examine the effects of increased dietary sodium chloride in a human in vivo system. The investigators hypothesize that excess dietary salt may function as an environmental trigger that favors induction and expansion of pathogenic Th17 cells and leads to functional impairment of Tregs, thereby favoring development of autoimmunity. The investigators aim to study their established in vitro model in humans by altering the salt intake in patients over a 20-day period.

Interventions

On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.

On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.

Sponsors

Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
1 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults 18-50 years of age * Children 1-17 years of age * ALT and/or ALP/GGT level \> 2X upper limit of normal * ANA or SMA \>/= 1:40 * ANA or SMA \>/= 1:80 * or LKM \>/= 1:40 * or SLA positive * IgG \> upper limit of normal

Exclusion criteria

* Chronic hepatitis C * Decompensated Liver Disease

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in production of pathogenic TH17 cells.26 daysMeasuring TH17 cells by flow cytometry and qRT-PCR. There are no known normal ranges. The investigator will calculate the change by observing the difference from baseline values.

Secondary

MeasureTime frameDescription
Change from baseline in regulatory T cell function.26 daysMeasuring T cell function by flow cytometry. There are no known normal ranges. The investigator will calculate the change by observing the difference from baseline values.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026